Natural killer (NK) cells are the human body’s first line of defense against cancer and infections but tend to get knocked down by treatment with anti-CD38 antibodies. This is because NK cells ...

Felzartamab is a human monoclonal antibody that targets the cluster of differentiation 38 (CD38) and is tailored to minimise ...

Its Product Pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia ...

Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of HexaBody-CD38. “While we are disappointed that J&J has decided not to advance ...

The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.